Lower-price drugs would hit the market faster under a bipartisan bill awaiting a vote in the Senate, according to a score released Wednesday by the Congressional Budget Office and the Joint Committee on Taxation.

“CBO expects that the bill’s provisions would allow generic drugs … to enter the market earlier, on average, than they would under current law,” authors of the report concluded.

Recommended Stories

Dr. Oz and FDA chief say biosimilar drug reform will lower prices

Trump’s drug-price crackdown misses the mark, experts say

FDA proposes hospital subscriptions to medicines to fight deadly drug-resistant bacteria